Professor Jan Lundberg has more than 25 years of experience from leading positions in global pharmaceutical companies, including as global head of research at Astra and then AstraZeneca (1996 – 2009) and global head of research and development at Eli Lilly (2010 – 2018). He has led the development of more than 200 drug candidates, including Alzheimer's and pain, with 30 approved products in several therapeutic areas. Furthermore, Dr. Lundberg co-founded the medtech company Aerocrine, which was later acquired by British Circassia Pharmaceuticals for SEK 1.78 billion in 2015.

Before joining Astra, Dr. Lundberg was professor of pharmacology at the Karolinska Institute in Sweden, where he also received his PhD. He also studied medicine at the University of Gothenburg for four years and his research has resulted in over 500 publications in peer-reviewed scientific journals.

Dr. Lundberg is also an honorary doctorate at the Faculty of Pharmacology at Uppsala University, Sweden and has received both the Fernström and Jahre prizes. Over the years, he has also been active in several international authority committees. He is currently a board member of several different pharmaceutical and biotechnology companies, and his extensive experience in research and development with a strong interest in central nervous system diseases will be a great asset to AlzeCure.

"AlzeCure has a fantastically exciting and promising project portfolio in areas of very high medical need and in fields that I worked with. I am happy to be able to join the company in this exciting development phase and to contribute to the company's continued success," said Dr. Jan Lundberg.

"We are incredibly grateful and happy that Jan Lundberg has been elected a board member, and we are convinced that his experience and knowledge will make a very positive contribution to our continued future successful development,” said Martin Jönsson, CEO of AlzeCure Pharma.